nejm tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes Tirzepatide outperforms semaglutide in NEJM

JAMA 311 , 16411651 (2014)

Gerry Fegan, Yeap BB, et al

Effets secondaires Les mdecins sinquitent aussi des effets secondaires du smaglutide, sous-notifis selon le Pr Faillie, en charge de sa pharmacovigilance

It drives feeding behavior between meals, promotes NPY and AgRP release in the arcuate nucleus, and upregulates adipose tissue storage

One spot for affordable GLP-1 options Many patients may have copays as low as $25* a month with commercial insurance and a manufacturer coupon, or $149* a month without insurance, with a manufacturer coupon

This difference in metabolic pathways means that the timing of administration can significantly impact how each drug affects the body, making it essential to follow a healthcare provider's recommendations regarding dosing schedules